Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1/2

NCT05010122

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My…

This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib i…

United States42 participantsStarted 2021-07-08

Treatment: Decitabine and Cedazuridine, Gilteritinib

All recent trials (5 shown)

CompletedPhase 2

NCT01522469

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

This is a Phase II open label study of crenolanib besylate. This study will enroll subjects with relapsed or refractory AML with FLT3 activating mutations. Prio…

United States14 participantsStarted 2012-07

Treatment: Crenolanib Besylate (CP-868,596-26)

CompletedPhase 2

NCT01657682

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

This pilot Phase II study is designed to evaluate the efficacy and tolerability of crenolanib in two cohorts of AML patients with FLT3 activation mutations (pat…

United States56 participantsStarted 2012-10

Treatment: Crenolanib besylate

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My…

All recent trials (5 shown)

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My…

All recent trials (5 shown)

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and…

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation